Ocular Complications of Antineoplastic Therapies

References

• KondoN , TakahashiA , OnoK , OhnishiT. DNA damage induced by alkylating agents and repair pathways. J. Nucleic Acids.2010, 543531 (2010).
   PubMedGoogle Scholar
• BrownA , KumarS , TchounwouPB. Cisplatin-Based Chemotherapy of Human Cancers. J. Cancer Sci. Ther.11(4), 97 (2019).
   PubMedGoogle Scholar
• LiY , LiY , LiJ , PiG , TanW. Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review. Onco. Targets Ther.7, 1361–1366 (2014).
   PubMed Web of Science ®Google Scholar
• WildingG , CarusoR , LawrenceTSet al.Retinal toxicity after high-dose cisplatin therapy. J. Clin. Oncol.3(12), 1683–1689 (1985).
   PubMed Web of Science ®Google Scholar
• CaraceniA , MartiniC , SpattiG , ThomasA , OnofrjM. Recovering optic neuritis during systemic cisplatin and carboplatin chemotherapy. Acta. Neurol. Scand.96(4), 260–261 (1997).
   PubMed Web of Science ®Google Scholar
• PippittCHJr , MussHB , HomesleyHD , JobsonVW. Cisplatin-associated cortical blindness. Gynecol. Oncol.12, 253–255 (1981).
   PubMed Web of Science ®Google Scholar
• CohenRJ , CuneoRA , CrucigerMP , JackmanAE. Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin. J. Clin. Oncol.1(6), 392–393 (1983).
   PubMed Web of Science ®Google Scholar
• NatarajanG , MalathiR , HollerE. Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem. Pharmacol.58(10), 1625–1629 (1999).
   PubMed Web of Science ®Google Scholar
• RankinEM , PittsJF. Ophthalmic toxicity during carboplatin therapy. Ann. Oncol.4(4), 337–338 (1993).
   PubMed Web of Science ®Google Scholar
• MulvihillA , BudningA , JayVet al.Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch. Ophthalmol.121(8), 1120–1124 (2003).
   PubMedGoogle Scholar
• KwanAS , SahuA , PalexesG. Retinal ischemia with neovascularization in cisplatin related retinal toxicity. Am. J. Ophthalmol.141(1), 196–197 (2006).
   PubMed Web of Science ®Google Scholar
• ColvinOM. An overview of cyclophosphamide development and clinical applications. Curr. Pharm. Des.5(8), 555–560 (1999).
   PubMed Web of Science ®Google Scholar
• JackMK , HicksJD. Ocular complications in high-dose chemoradiotherapy and marrow transplantation. Ann. Ophthalmol.13(6), 709–711 (1981).
   PubMedGoogle Scholar
• KendeG , SirkinSR , ThomasPR , FreemanAI. Blurring of vision: a previously undescribed complication of cyclophosphamide therapy. Cancer44(1), 69–71 (1979).
   PubMed Web of Science ®Google Scholar
• StevensA , SpoonerD. Lacrimal duct stenosis and other ocular toxicity associated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy for early stage breast cancer. Clin. Oncol. (R. Coll. Radiol.).13(6), 438–440 (2001).
   PubMed Web of Science ®Google Scholar
• ShingletonBJ , BienfangDC , AlbertDM , EnsmingerWD , ChandlerWF , GreenbergHS. Ocular toxicity associated with high-dose carmustine. Arch. Ophthalmol.100(11), 1766–1772 (1982).
   PubMed Web of Science ®Google Scholar
• GrimsonBS , MahaleyMSJr , DubeyHD , DudkaL. Ophthalmic and central nervous system complications following intracarotid BCNU (Carmustine). J Clin. Neuroophthalmol.1(4), 261–264 (1981).
   PubMedGoogle Scholar
• LouieAC , TurrisiAT , MuggiaFM , BonoVHJr. Visual abnormalities following nitrosourea treatment. Med. Pediatr. Oncol.5(1), 245–247 (1978).
   PubMedGoogle Scholar
• JohnsonDW , CagnoniPJ , SchossauTMet al.Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support. Bone Marrow Transplant.24(7), 785–792 (1999).
   PubMed Web of Science ®Google Scholar
• ChrousosGA , OldfieldEH , DoppmanJL , CoganDG. Prevention of ocular toxicity of carmustine (BCNU) with supraophthalmic intracarotid infusion. Ophthalmology93(11), 1471–1475 (1986).
   PubMed Web of Science ®Google Scholar
• NakamuraT , UedaT , UchidaM. Gan To Kagaku Ryoho.19(3), 409–420 (1992).
   PubMedGoogle Scholar
• RitchPS , HansenRM , HeuerDK. Ocular toxicity from high-dose cytosine arabinoside. Cancer51(3), 430–432 (1983).
   PubMed Web of Science ®Google Scholar
• MargilethDA , PoplackDG , PizzoPA , LeventhalBG. Blindness during remission in two patients with acute lymphoblastic leukemia: a possible complication of multimodality therapy. Cancer39(1), 58–61 (1977).
   PubMed Web of Science ®Google Scholar
• HigaGM , GockermanJP , HuntAL , JonesMR , HorneBJ. The use of prophylactic eye drops during high-dose cytosine arabinoside therapy. Cancer68(8), 1691–1693 (1991).
   PubMed Web of Science ®Google Scholar
• ÖzcanG , UçakhanÖÖ. Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients. Turk. J.Ophthalmol.51(2), 114–117 (2021).
   PubMedGoogle Scholar
• ZhangN , YinY , XuSJ , ChenWS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules.13(8), 1551–1569 (2008).
   PubMed Web of Science ®Google Scholar
• KhawPT , SherwoodMB , MacKaySL , RossiMJ , SchultzG. Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule fibroblasts. Arch. Ophthalmol.110(8), 1150–1154 (1992).
   PubMedGoogle Scholar
• ShapiroMS , ThoftRA , FriendJ , ParrishRK , GresselMG. 5-Fluorouracil toxicity to the ocular surface epithelium. Invest. Ophthalmol. Vis. Sci.26(4), 580–583 (1985).
   PubMed Web of Science ®Google Scholar
• BrinkHM , BeexLV. Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature. Doc. Ophthalmol.90(1), 1–6 (1995).
   PubMed Web of Science ®Google Scholar
• EisemanAS , FlanaganJC , BrooksAB , MitchellEP , PembertonCH. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. Ophthalmic Plast. Reconstr. Surg.19(3), 216–224 (2003).
   PubMed Web of Science ®Google Scholar
• BukhariDA , AlessaSK , BeheiriSI. Corneal Epithelial Hyperplasia after 5-Fluorouracil Injection. Case Rep. Ophthalmol.9(1), 254–256 (2018).
   PubMedGoogle Scholar
• RainaAJ , GilbarPJ , GrewalGD , HolcombeDJ. Optic neuritis induced by 5-fluorouracil chemotherapy: case report and review of the literature. J. Oncol. Pharm. Pract.26(2), 511–516 (2020).
   PubMed Web of Science ®Google Scholar
• ChristophidisN , VajdaFJ , LucasI , LouisWJ. Ocular side effects with 5-fluorouracil. Aust. N. Z. J. Med.9(2), 143–144 (1979).
   PubMedGoogle Scholar
• AndersonBJr. Necrotizing uveitis incident to perfusion of intractraial malignancies with nitrogen mustard or related compounds. Trans. Am. Ophthalmol. Soc.58, 95–104 (1960).
   PubMedGoogle Scholar
• al-TweigeriT , NabholtzJM , MackeyJR. Ocular toxicity and cancer chemotherapy. A review. Cancer78(7), 1359–1373 (1996).
   PubMed Web of Science ®Google Scholar
• ChoonaraIA , OverendM , BaileyCC. Blurring of vision due to ifosfamide. Cancer Chemother. Pharmacol.20(4), 349 (1987).
   PubMed Web of Science ®Google Scholar
• SimpsonD , DunnC , CurranM , GoaKL. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs63(19), 2127–2156 (2003).
   PubMed Web of Science ®Google Scholar
• WaikhomB , FraunfelderFT , HennerWD. Severe ocular irritation and corneal deposits associated with capecitabine use. N. Engl. J. Med.343, 740–741 (2000).
   PubMed Web of Science ®Google Scholar
• KunklerAL , BinkleyEM , MantopoulosDet al.Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics. Graefes Arch Clin. Exp. Ophthalmol.257(8), 1771–1781 (2019).
   PubMed Web of Science ®Google Scholar
• ChunHG , Leyland-JonesBR , CarykSM , HothDF. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep.70(10), 1225–1228 (1986).
   PubMedGoogle Scholar
• KordValeshabad A , MielerWF , SetlurV , ThomasM , ShahidiM. Posterior segment toxicity after gemcitabine and docetaxel chemotherapy. Optom. Vis. Sci.92(5), e110–e113 (2015).
   PubMedGoogle Scholar
• GreverMR , DoanCA , KrautEH. Pentostatin in the treatment of hairy-cell leukemia. Best Pract. Res. Clin. Haematol.16(1), 91–99 (2003).
   PubMed Web of Science ®Google Scholar
• VizelM , OsterMW. Ocular side effects of cancer chemotherapy. Cancer49(10), 1999–2002 (1982).
   PubMed Web of Science ®Google Scholar
• CapriG , MunzoneE , TarenziEet al.Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J. Natl Cancer Inst.86(14), 1099–1101 (1994).
   PubMedGoogle Scholar
• SkolnickCA , DoughmanDJ. Erosive conjunctivitis and punctual stenosis secondary to docetaxel (taxotere). Eye Contact Lens.29(2), 134–135 (2003).
   PubMedGoogle Scholar
• PaulMK , MukhopadhyayAK. Tyrosine kinase - Role and significance in Cancer. Int. J. Med. Sci.1(2), 101–115 (2004).
   PubMedGoogle Scholar
• JiaoQ , BiL , RenY , SongS , WangQ , WangYS. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol. Cancer.17(1), 36 (2018).
   PubMedGoogle Scholar
• ThomsonRJ , MoshirfarM , RonquilloY. Tyrosine Kinase Inhibitors. In: StatPearls [Internet].StatPearls Publishing, FL, USA (2023).
   Google Scholar
• AnX , TiwariAK , SunY , DingPR , AshbyCRJr , ChenZS. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk. Res.34(10), 1255–1268 (2010).
   PubMed Web of Science ®Google Scholar
• IqbalN , IqbalN. Imatinib: a breakthrough of targeted therapy in cancer. Chemother. Res. Pract.2014, 357027 (2014).
   PubMedGoogle Scholar
• FuC , GombosDS , LeeJet al.Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions [published correction appears in Oncotarget. Oncotarget10(9), 1011–1013 (2019).
   PubMedGoogle Scholar
• FraunfelderFW , SolomonJ , DrukerBJ , EsmaeliB , KuylJ. Ocular side-effects associated with imatinib mesylate (Gleevec). J. Ocul. Pharmacol. Ther.19(4), 371–375 (2003).
   PubMed Web of Science ®Google Scholar
• McClellandCM , HarocoposGJ , CusterPL. Periorbital edema secondary to imatinib mesylate. Clin. Ophthalmol.4, 427–431 (2010).
   PubMedGoogle Scholar
• YılmazF , AlbayrakM , TığlıoğluPet al.Vitreous hemorrhage: a rare ophthalmic adverse effect due to imatinib treatment. Journal of Oncology Pharmacy Practice.28(3), 725–728 (2022).
   PubMed Web of Science ®Google Scholar
• LiuPCC , KoblishH , WuLet al.INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLOS One.15(4), e0231877 (2020).
   PubMed Web of Science ®Google Scholar
• AlekseevO , OjuokE , CousinsS. Multifocal serous retinopathy with pemigatinibtherapy for metastatic colon adenocarcinoma. Int. J. Retin. Vitr.7, 34 (2021).
   PubMedGoogle Scholar
• BloomWR , EdakkunnathuA , KondapalliSS , BloomTD. Transient pemigatinib-induced subretinal fluid accumulation and serous retinal detachment. Clin. Exp. Optom.1–410.1080/08164622.2022.2086792 (2022).
   Web of Science ®Google Scholar
• CortesJE , KimDW , Pinilla-IbarzJet al.Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood132(4), 393–404 doi:10.1182/blood-2016-09-739086 (2018).
   PubMed Web of Science ®Google Scholar
• ShinE , LimDH , HanJet al.Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. BMC Ophthalmol20, 19 (2020).
   PubMed Web of Science ®Google Scholar
• BurgerJA. Bruton Tyrosine Kinase Inhibitors: Present and Future. Cancer J.25(6), 386–393 (2019).
   PubMed Web of Science ®Google Scholar
• MehrabanFar P , RulloJ , FarmerJ , UrtonT. Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia. Ocul. Immunol. Inflamm.30(4), 1005–1008 (2022).
   PubMed Web of Science ®Google Scholar
• BohnM , Bravo-LjubeticL , LeeRWJ , PetrushkinH. Ibrutinib-related uveitis: a report of two severe cases. Eur. J. Ophthalmol.32(4), NP94–NP97 (2022).
   PubMed Web of Science ®Google Scholar
• ByrdJ , O'BrienS , BarrientosJCet al.Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Eng. J. Med.371, 213–223 (2014).
   PubMed Web of Science ®Google Scholar
• FuC , GombosDS , LeeJet al.Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget.8(35), 58709–58727 (2017).
   PubMedGoogle Scholar
• ProiettiI , SkrozaN , MicheliniSet al.BRAF inhibitors: molecular targeting and immunomodulatory actions. Cancers (Basel).12(7), 1823 (2020).
   PubMed Web of Science ®Google Scholar
• ChoeCH , McArthurGA , CaroI , KempenJH , AmaravadiRK. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am. J. Ophthalmol.158(4), 831–837 (2014).
   PubMed Web of Science ®Google Scholar
• ChengY , TianH. Current Development Status of MEK Inhibitors. Molecules.22(10), 1551 (2017).
   PubMed Web of Science ®Google Scholar
• WrightCJ , McCormackPL. Trametinib: first global approval.. Drugs73(11), 1245-54 (2013). https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm354478.htm
   PubMed Web of Science ®Google Scholar
• DuncanK , ChangL , PatronasM. MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity. Eye29, 1003–1012 (2015).
   PubMed Web of Science ®Google Scholar
• Méndez-MartínezS , CalvoP , Ruiz-MorenoOet al.OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS. Retina.39(8), 1435–1450 (2019).
   PubMed Web of Science ®Google Scholar
• SarnyS , NeumayerM , KoflerJ , El-ShabrawiY. Ocular toxicity due to trametinib and dabrafenib. BMC Ophthalmol.17(1), 146 (2017).
   PubMedGoogle Scholar
• RoskoskiRJr. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Pharmacol. Res.117, 343–356 (2017).
   PubMed Web of Science ®Google Scholar
• ChelalaE , HoyekS , ArejN , BaaklinyJ , AntounJ. Ocular and orbital side effects of ALK inhibitors: a review article. Future Oncol.15(16), 1939–1945 (2019).
   PubMed Web of Science ®Google Scholar
• AhmadR , MehtaH. The ocular adverse effects of oral drugs. Aust Prescr.44(5), 177 (2021).
   Google Scholar
• WeiSC , DuffyCR , AllisonJP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov.8(9), 1069–1086 (2018).
   PubMed Web of Science ®Google Scholar
• DalvinLA , ShieldsCL , OrloffM , SatoT , ShieldsJA. Checkpoint Inhibitor immune therapy: Systemic Indications and Ophthalmic Side Effects. Retina.38(6), 1063–1078 (2018).
   PubMed Web of Science ®Google Scholar
• NguyenM , IslamMR , LimSW , SahuA , TamjidB. Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis. Front Oncol.9, 944 (2019).
   PubMed Web of Science ®Google Scholar
• ChanprapaphK , VachiramonV , RattanakaemakornP. Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatol. Res. Pract.2014, 734249 (2014).
   PubMedGoogle Scholar
• DuboisEA , CohenAF. Panitumumab. Br. J. Clin. Pharmacol.68(4), 482–483 (2009).
   PubMed Web of Science ®Google Scholar
• ShahrokniA , MatuszczakJ , RajebiMR , SaifMW. Erlotinib-induced episcleritis in a patient with pancreatic cancer. JOP.9(2), 216–219 (2008).
   PubMedGoogle Scholar
• GiustiRM , ShastriK , PilaroAMet al.U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin. Cancer Res.14(5), 1296–1302 (2008).
   PubMed Web of Science ®Google Scholar
• VaxmanI , AbeykoonJ , DispenzieriAet al.“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience. Blood Cancer J.11, 196 (2021).
   PubMed Web of Science ®Google Scholar
• WahabA , RafaeA , MushtaqK , KhakwaniM , KhanA. Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma. Front Oncol.11, 678634 (2021).
   PubMed Web of Science ®Google Scholar
• Randall , KatrinaL. Rituximab in autoimmune diseases. Australian Prescriber39(4), 131–134 doi:10.18773/austprescr.2016.053 (2016).
   PubMedGoogle Scholar
• CernyT , BorischB , IntronaM , JohnsonP , RoseAL. Mechanism of action of rituximab. Anticancer Drugs13(Suppl. 2), S3–S10 (2002).
   PubMed Web of Science ®Google Scholar
• MCastillejo Becerra C , DingY , KenolB , HendershotA , MearaAS. Ocular side effects of antirheumatic medications: a qualitative review. BMJ Open Ophthalmology5, e000331 (2020).
   PubMed Web of Science ®Google Scholar
• ForanJM , RohatinerAZ , CunninghamDet al.European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma [published correction appears in J Clin Oncol 2000 May;18(9):2006]. J. Clin. Oncol.18(2), 317–324 (2000).
   PubMed Web of Science ®Google Scholar
• LeeYH , KimCH. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives. Arch. Pharm. Res.42, 607–616 (2019).
   PubMed Web of Science ®Google Scholar
• MumtazAA , FischerA , LutfiFet al.Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review. Br. J. Ophthalmol.10.1136/bjophthalmol-2021-320814 (2020).
   Web of Science ®Google Scholar
• AndrewFischer , AlbertLi. CAR T-Cell Therapy Associated Ocular Adverse Events Reported to the Food and Drug Administration. Invest. Ophthalmol. Vis. Sci.61(7), 3636 (2020).
   Web of Science ®Google Scholar
• NunesAT , AnnunziataCM. Proteasome inhibitors: structure and function. Semin. Oncol.44(6), 377–380 (2017).
   PubMed Web of Science ®Google Scholar
• SharmaA , PreussCV. Bortezomib. [Updated 2022 Sep 21]. In: StatPearls [Internet].StatPearls Publishing, FL, USA (2023).
   Google Scholar
• SklarBA , GervasioKA , LengS , GhoshA , ChariA , WuAY. Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series. BMC Ophthalmol.19(1), 110 (2019).
   PubMedGoogle Scholar
• VeysMC , DelforgeM , MombaertsI. Treatment with doxycycline for severe bortezomib-associated blepharitis. Clin Lymphoma Myeloma Leuk.16(7), e109–e112 (2016).
   PubMed Web of Science ®Google Scholar
• FoersterCG , CursiefenC , KruseFE. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea27(5), 612–614 (2008).
   PubMed Web of Science ®Google Scholar
• TodokoroD , ItakuraH , IbeT , KishiS. Anterior uveitis caused by ocular side effects of afatinib: a case report. Case Rep. Ophthalmol.7(1), 74–78 (2016).
   PubMedGoogle Scholar
• DavisME. Ocular Toxicity of Tyrosine Kinase Inhibitors. Oncol. Nurs. Forum.43(2), 235–243 (2016).
   PubMed Web of Science ®Google Scholar
• LoriotY , NecchiA , ParkSHet al.Erdafitinib in locally advanced or metastatic urothelial carcinoma. N. Engl. J. Med.381(4), 338–348 (2019).
   PubMed Web of Science ®Google Scholar
• ChangM , KuriakoseRK , XuK , AlmeidaDRP , ChinEK. Chronic Unilateral Uveitis with Macular Edema Secondary to Dabrafenib for Pilocytic Astrocytoma. Case Rep. Ophthalmol12, 574–577 (2021).
   PubMed Web of Science ®Google Scholar
• SullivanRJ , WeberJ , PatelSet al.A phase Ib/II study of the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib in patients with BRAFV600E/K -mutant solid tumors. Clin Cancer Res.26(19), 5102–5112 (2020).
   PubMed Web of Science ®Google Scholar
• Urner-BlochU , UrnerM , StiegerP , FrauchigerAL , DummerR , GoldingerSM. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann. Oncol.25(7), 1437–1441 (2014).
   PubMed Web of Science ®Google Scholar
• WatanabeK , OtsuS , HirashimaYet al.A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol.77(6), 1157–1164 (2016).
   PubMed Web of Science ®Google Scholar
• StjepanovicN , Velazquez-MartinJP , BedardPL. Ocular toxicities of MEK inhibitors and other targeted therapies. Ann. Oncol.27(6), 998–1005 (2016).
   PubMed Web of Science ®Google Scholar
• TarhiniA. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo).2013, 857519 (2013).
   PubMedGoogle Scholar
• PavlidisNA , PetrisC , BriassoulisEet al.Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer69(12), 2961–2964 (1992).
   PubMed Web of Science ®Google Scholar
• AshfordAR , DonevI , TiwariRP , GarrettTJ. Reversible ocular toxicity related to tamoxifen therapy. Cancer61(1), 33–35 (1988).
   PubMed Web of Science ®Google Scholar